Actively Recruiting
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-27
145
Participants Needed
12
Research Sites
415 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
CONDITIONS
Official Title
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Metastatic breast cancer (all subtypes) or non-small cell lung cancer without targetable molecular alterations or with progression on first-line tyrosine kinase inhibitor
- Newly diagnosed metastatic disease or stable disease on systemic therapy for at least 3 months
- Measurable disease at baseline with 5 or fewer discrete sites suitable for SBRT
- Primary tumor or local disease must be treatable with SBRT or conventional/hypofractionated radiotherapy
- Prior local therapy for primary disease allowed if recurrent disease is treatable with SBRT or hypofractionated radiation
- Palliative radiotherapy for symptoms allowed prior to enrollment if at least one untreated lesion is eligible for SBRT
- Previously treated brain metastases allowed
- ECOG performance status of 0 to 2
- Age 18 years or older
- Able to provide informed consent
- Female participants must be non-reproductive or have a negative pregnancy test within 2 weeks prior to treatment
- Adequate organ function to allow SBRT as determined by treating radiation oncologist
You will not qualify if you...
- Serious health conditions preventing radiotherapy as judged by the investigator
- Pregnant or breastfeeding women
- Other active cancers within the past year
- Evidence of spinal cord compression
- Presence of malignant pleural effusion or ascites
- Participation would cause unacceptable delays in planned treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Natera, Inc. (Data and Specimen Analysis Only)
San Carlos, California, United States, 94070
Not Yet Recruiting
2
Hartford Healthcare
Hartford, Connecticut, United States, 06102
Actively Recruiting
3
WCHN Norwalk Hospital - Data Collection
Norwalk, Connecticut, United States, 06850
Actively Recruiting
4
Baptist Alliance - McI
Miami, Florida, United States, 33143
Actively Recruiting
5
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
6
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States, 07748
Actively Recruiting
7
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States, 07645
Actively Recruiting
8
Memorial Sloan Kettering Cancer Center @ Commack
Commack, New York, United States, 11725
Actively Recruiting
9
Memorial Sloan Kettering Westchester
Harrison, New York, United States, 10604
Actively Recruiting
10
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
11
Memorial Sloan Kettering Nassau
Uniondale, New York, United States, 11553
Actively Recruiting
12
Lehigh Valley Health Network
Allentown, Pennsylvania, United States, 18103
Actively Recruiting
Research Team
A
Amy Xu, MD, PhD
CONTACT
W
Wanqing Zhi, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here